Arcus Biosciences (RCUS) awards 96k options and 24k RSUs

Rhea-AI Filing Summary

Arcus Biosciences granted equity awards to its General Counsel, Carolyn C. Tang. She received 24,000 shares of common stock in the form of restricted stock units at a grant price of $0. These RSUs vest in four equal annual installments beginning on December 15, 2026, conditioned on her continued service with the company.

She was also granted a stock option for 96,000 shares of common stock with an exercise price of $22.13 per share. This option becomes exercisable in 48 equal monthly installments after January 1, 2026, also subject to continued service. Following these transactions, Tang directly beneficially owns 148,734 shares of common stock, which includes unvested RSUs, and holds 96,000 stock options.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Tang Carolyn C.

Role General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	96,000	$0.00	--
Grant/Award	Common Stock	24,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 96,000 shares (Direct); Common Stock — 148,734 shares (Direct)

Footnotes (1)

1. Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company. Includes the unvested portion of the Reporting Person's RSU grants. The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tang Carolyn C.

(Last) (First) (Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		A		24,000(1)	A	$0	148,734(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$22.13	01/23/2026		A		96,000		(3)	01/22/2036	Common Stock	96,000	$0	96,000	D

Explanation of Responses:

1. Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.

2. Includes the unvested portion of the Reporting Person's RSU grants.

3. The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.

Remarks:

	/s/ Carolyn Tang, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider equity awards were reported for Arcus Biosciences (RCUS)?

The filing reports that General Counsel Carolyn C. Tang received 24,000 restricted stock units of common stock and a stock option for 96,000 shares of Arcus Biosciences common stock.

What are the vesting terms of the 24,000 RSUs granted to the Arcus Biosciences General Counsel?

The 24,000 RSUs vest in four equal annual installments beginning on December 15, 2026, subject to Carolyn C. Tang’s continued service to the company.

What is the exercise price and vesting schedule of the 96,000 stock options at Arcus Biosciences (RCUS)?

The stock option covers 96,000 shares of common stock with an exercise price of $22.13 per share. It becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to continued service.

How many Arcus Biosciences shares does the General Counsel own after this Form 4?

After these equity awards, Carolyn C. Tang beneficially owns 148,734 shares of common stock directly, which includes the unvested portion of her RSU grants, and holds 96,000 stock options.

Were these Arcus Biosciences (RCUS) insider transactions purchases or grants?

The transactions reported are grants of equity compensation: restricted stock units and stock options, each shown with a transaction code "A" for acquisition and a grant price of $0 for the awards.

What role does the reporting person hold at Arcus Biosciences?

The reporting person, Carolyn C. Tang, is an officer of Arcus Biosciences serving as General Counsel, as stated in the filing.